Syntaxin raises $33M for biologics

11/1/2007 | Reuters

GlaxoSmithKline's venture-capital unit SR One co-led a new funding round that raised $33 million for Syntaxin Ltd. The firm is trying to develop experimental biologics for the treatment of pain and nervous, respiratory and metabolic disorders using a protein-based technology that controls the aberrant secretion of hormones linked to diseases.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care